{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Benderski K"],"funding":["European Research Council","Deutsche Forschungsgemeinschaft (German Research Foundation)"],"pagination":["1163-1172"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12373501"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(8)"],"pubmed_abstract":["Multi-drug nanomedicine is gaining momentum for co-delivering more than one drug to the same site at the same time. Our analysis of 273 pre-clinical tumour growth inhibition studies shows that multi-drug nanotherapy outperforms single-drug therapy, multi-drug combination therapy, and single-drug nanotherapy by 43, 29 and 30%, respectively. Combination nanotherapy also results in the best overall survival rates, with 56% of studies demonstrating complete or partial survival, versus 20-37% for control regimens. Within the multi-drug nanomedicine groups, we analysed the effect of (co-)administration schedule and strategy, passive versus active targeting, nanocarrier material and the type of therapeutic agent. Most importantly, it was found that co-encapsulating two different drugs in the same"],"journal":["Nature nanotechnology"],"pubmed_title":["Analysis of multi-drug cancer nanomedicine."],"pmcid":["PMC12373501"],"funding_grant_id":["KFO344","864121","SFB1066"],"pubmed_authors":["Benderski K","Lammers T","Sofias AM"],"additional_accession":[]},"is_claimable":false,"name":"Analysis of multi-drug cancer nanomedicine.","description":"Multi-drug nanomedicine is gaining momentum for co-delivering more than one drug to the same site at the same time. Our analysis of 273 pre-clinical tumour growth inhibition studies shows that multi-drug nanotherapy outperforms single-drug therapy, multi-drug combination therapy, and single-drug nanotherapy by 43, 29 and 30%, respectively. Combination nanotherapy also results in the best overall survival rates, with 56% of studies demonstrating complete or partial survival, versus 20-37% for control regimens. Within the multi-drug nanomedicine groups, we analysed the effect of (co-)administration schedule and strategy, passive versus active targeting, nanocarrier material and the type of therapeutic agent. Most importantly, it was found that co-encapsulating two different drugs in the same","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-09T10:39:38.614Z","creation":"2026-04-08T00:48:19.152Z"},"accession":"S-EPMC12373501","cross_references":{"pubmed":["40374796"],"doi":["10.1038/s41565-025-01932-1"]}}